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ABSTRACT 
Objective. To assess immunologically relevant outcomes in a cohort of RA patients 
with long-term therapy-induced lymphopenia. 
Methods. Fifty three RA patients who received the lymphocytotoxic monoclonal 
antibody CAMPATH-1H (alemtuzumab, MabCampath®) between 1991 and 1994 
were assessed for mortality, and infectious and malignant morbidity using interviews, 
case note review and NHS Central Registry mortality monitoring. Lymphocyte 
subsets were enumerated by flow cytometry. A retrospective, matched-cohort study 
of mortality was performed with 102 control subjects selected from the EULAR 
database of patients with rheumatic disorders. 
Results. Patients remained lymphopenic: median CD3+CD4+, CD3+CD8+, CD19+ and 
CD56+ lymphocyte counts measured at a mean follow-up of 11.8 years from first 
dose of CAMPATH-1H were 0.59, 0.275, 0.13 and 0.105 x 109 / L respectively. 27 of 
51 cases and 46 of 101 controls had died, providing a mortality rate ratio of 1.20 
(95% CI 0.72-1.98). Causes of death were similar to those expected for a hospital-
based RA cohort. No opportunistic infections were noted and only 3 infections 
documented following 36 elective orthopaedic procedures.  
 Conclusions. Despite continued lymphopenia 11.8 years after therapy, our patient 
cohort does not display excess mortality or unusual infectious morbidity and surgery 
is well tolerated. These data are reassuring for clinicians and patients considering 
lymphocytotoxic or other immunomodulatory therapy for RA. 
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CAMPATH-1H (Alemtuzumab, MabCampath®) was the first humanised therapeutic 
monoclonal antibody (mAb). It recognises CD52, a highly glycosylated, GPI-
anchored, peptide of unknown function that is present on T and B lymphocytes, 
monocytes and NK cells(1). In the early 1990s a number of clinical trials studied the 
response to CAMPATH-1H in patients with refractory rheumatoid arthritis (RA) 
(summarised in (2)). The rationale was that lymphocyte depletion and reconstitution 
would result in autoreactive lymphocytes being replaced by a tolerant immune 
system. Trials were curtailed largely as a consequence of delayed reconstitution, 
particularly of T-lymphocytes, resulting in a cohort of profoundly lymphopenic patients 
(3).  
In a previous study we demonstrated that, despite continued lymphopenia for a 
median of 6 years from therapy, there was no detectable consequence on mortality 
or infectious morbidity in RA recipients of CAMPATH-1H (3). The progress of this 
cohort remains relevant for several reasons: CAMPATH-1H continues to be 
developed for other autoimmune indications; alternative lymphocytotoxic regimes, 
such as high-dose cyclophosphamide with stem cell rescue, may carry similar long-
term implications; and Rituximab, a B-cell depleting therapy, has recently gained a 
licence for use in RA. In the current study we extend follow-up of our cohort to a 
median of 12 years.  
PATIENTS AND METHODS 
Patients and controls 
Patients treated with CAMPATH -1H between 1991 and 1994 in Cambridge (UK) 
were identified from the study database. Follow up information was obtained for 
patients who were alive on 31st December 1998 (conclusion of our previous study). 
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Morbidity data was collected up to 31st December 2004 and mortality data to 9th 
March 2006. Information was obtained as outlined previously (3). Particular attention 
was paid to episodes of infection and/or treatment with antibiotics, surgical 
procedures, cancers and other co-morbidities. For a retrospective, matched cohort 
study of mortality, the survival experience of our cohort was matched to patients 
entered into the European League Against Rheumatism (EULAR) database for 
patients with rheumatic disorders who have received immunosuppressive agents (6), 
as previously described (3).  
Of the original 53 patients, 13 deaths were described previously (3). There were 14 
additional deaths in the current follow-up period. 5 patients could not be contacted, 
including 3 previously reported lost to follow-up. Only one of these patients is known 
to have emigrated, and therefore we will be informed if any of the other 4 die (as a 
consequence of ‘flagging’ with the National Health Service Central Registry (3)). 20 
patients were interviewed for the current study (including 3 that subsequently died) 
and hospital notes were reviewed for 5 patients (including one that died after 
consenting to study inclusion).  
Lymphocyte subset analysis  
Lymphocyte subset analysis (CD3+CD4+ and CD3+CD8+ T cells, CD19+ B cells and 
CD56+ Natural Killer (NK) cells) was performed on peripheral blood from each patient 
that was interviewed.  
Statistical Analysis  
For mortality rate statistics, duration of follow-up was calculated to 9th March 2006 for 
the patients assumed to have remained in the UK (and therefore ‘flagged’), and to 
the last clinic visit for the patient known to have emigrated. For the retrospective, 
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matched cohort study, the mortality rates in cases and controls were obtained by 
dividing the number of deaths in each group by the number of person-years of follow-
up. The mortality rate ratio was obtained by dividing case mortality rate by control 
mortality rate. Kaplan-Meier survival curves were plotted using STATA software 
(Stata Corporation, College Station, TX). The log-rank test was used to compare 
survival between cases and controls and to compare survival in different CAMPATH-
1H dosing cohorts.  
Underlying cause of death was transcribed from death certificates using ICD9 or 
ICD10 codes. These were subsequently classified by ICD chapter, allowing a 
comparison of cause of death between cases and controls. Comparisons of mortality 
were examined using either chi-squared or Fisher’s exact tests, where groups 
contained a sufficient number of deaths. Deaths from neoplasms were analysed 
further utilising Poisson regression.  
RESULTS 
Demographics  
The pre-treatment cohort demographics were described previously (3). In brief, this 
was a cohort of refractory RA patients with mean age of 54 (range 25.5-70) years at 
the time of first treatment and median disease duration 9 (range 2-35) years. They 
had received a median of 4 DMARDs prior to CAMPATH-1H (range 1-8). 38 were 
female and 15 male. Details of the 25 surviving patients for whom information was 
available are documented in Table 1. The median (inter-quartile range [IQR]) time 
since first treatment with CAMPATH-1H to fail date was 12.7 (7.5 – 13.3) years for all 
study participants, 12.1 (6.0 – 13.2) years for cases and 12.8 (8.0 – 13.3) years for 
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controls. The total duration of follow-up for CAMPATH-1H treated patients was 
540.08 patient-years.  
Mortality  
Two cases could not be matched with appropriate controls and are excluded from the 
analysis (3). One control was excluded from the current analysis for a technical 
reason. Until 9th March 2006 there were 73 deaths - 27 of 51 cases and 46 of 101 
controls. The mortality rate for cases was 5 deaths per 100 person years and for 
controls was 4 per 100 person years, giving an incidence rate ratio of 1.20 (95% CI 
0.72-1.98). There was no difference in all-cause mortality rate between cases and 
controls (P=0.3894, log-rank test, Figure 1).  
The 14 previously unreported deaths are listed in Table 2A. Six were primarily 
cardiovascular (5 ischemic heart disease, one bowel infarction) and three due to 
infection (bronchopneumonia in each case), typical of an RA population. There were 
2 malignancies, 2 deaths from G-I causes and a death secondary to primary 
sclerosing cholangitis. Table 2B classifies all deaths reported since baseline, 
according to ICD chapter. Deaths from neoplasms and diseases of the digestive 
system were more common in cases than controls but this did not reach statistical 
significance. Deaths from neoplasms were analysed further utilising Poisson 
regression giving a mortality rate ratio of 3.33 (95% CI 0.85, 13.09), which was not 
statistically significant.  
Infections 
During the current morbidity follow-up period there were 3 major, definite infections 
where the causative pathogen was identified. Patient 1 sustained a left hip fracture. 
in 2002. This was fixed with a dynamic hip screw (DHS) which became infected with 
Isaacs JD Page 7 14/05/2008 
methicillin-resistant staphylococcus aureus (MRSA) necessitating its removal. In 
2003 the same patient developed septic arthritis of the right shoulder (pathogen not 
identified) which was surgically irrigated. This patient has since developed chronic 
ulceration of the left lower limb and an infected left 2nd metacarpophalangeal joint. 
Patient 10 developed cardiovascular collapse and a right knee aspirate grew beta 
haemolytic streptococcus. The patient made a full recovery with antimicrobial and 
supportive therapy. Patient 37 developed infection of the right first metatarso-
phalangeal joint from which staphylococcus, pseudomonas and diptheroids were 
cultured. The infection responded fully to treatment with clarithromycin and 
metronidazole. In November 1999 the same patient developed a chest infection 
which was treated with augmentin and in September 2002 disseminated herpes 
zoster infection which was treated with famciclovir.   
Patient 44 developed a number of soft tissue and joint infections, although the 
infecting organisms could not be identified from the case records. In June 2000 
antibiotics were prescribed for a wound infection following bilateral forefoot surgery. 
In 2003, whilst taking etanercept, antibiotics were prescribed for cellulitis of the lower 
leg and in June 2004 for a possible septic arthritis. Between October and December 
2004 intravenous antibiotics were administered for a septic arthritis of the elbow and 
an infected shoulder prosthesis, which was subsequently removed. Other patients 
have reported minor infections of the chest (patients 3,5,18,26,38) urinary tract 
(patient 26), ear (patient 32) and  skin (patient 41), each of which was successfully 
treated in the community with oral antimicrobial agents.  
Orthopaedic surgical procedures 
There were 36 elective orthopaedic interventions in 14 patients between December 
31st 1998 and December 31st 2004.  Three post-operative infections were recorded: 
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an infection of the hand following 5th extensor tendon repair, plus DHS and forefoot 
infections documented above. 
Non fatal malignancies 
Patient 14 was diagnosed with carcinoma of the breast in October 1999 and treated 
with lumpectomy and axillary lymph node excision. Patient 5 had a squamous cell 
carcinoma (SCC) removed from the right temple in 2003. This patient, described 
previously (3), was receiving immunosuppression following liver transplantation. 
Patients 16 and 37 had basal cell carcinomas removed from the face and patient 37 
also had a SCC removed from the face.  
Lymphocyte subsets 
The median CD3+CD4+, CD3+CD8+ and CD19+ lymphocyte counts measured 
between 157 and 180 months since the first dose of CAMPATH-1H were 0.59, 0.275, 
and 0.13 x 109 / L respectively (Table 1). In 2001 we reported equivalent values of 
0.185, 0.095 and 0.115 x 109 / L, 73 to 84 months post-therapy. This comparison 
demonstrates strong recovery of CD4+ T-cells in the intervening years, less marked 
recovery of CD8+ T-cells and surprisingly little movement in B-cell counts. It is 
particularly notable that most patients now have a CD3+CD4+ lymphocyte count 
within the reference range. CD3+CD8+ T-cell counts and NK cell counts remain sub-
normal in approximately 50% of subjects, and B-cell counts are low in the majority. 
CD56+ NK cell counts were not previously reported.  
DISCUSSION 
The development of CAMPATH-1H for RA was curtailed largely secondary to 
anxieties surrounding prolonged therapy-induced lymphopenia. At the time of the first 
CAMPATH-1H trials in RA, the prevailing dogma was that full reconstitution should 
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be expected following immune ablation. Subsequent studies, encompassing a variety 
of conditions, have emphasised factors which challenge that assumption (7) and our 
own work in RA has highlighted potential disease-specific factors such as impaired 
thymic function and defective immune homeostasis (8, 9). Ours is the longest 
reported follow-up of autoimmune patients following CAMPATH-1H and it is not yet 
possible to state with certainty whether the extreme delay in lymphocyte 
reconstitution is disease-specific (7, 9, 10). In this context it is reassuring to see 
CD4+ T-cell counts have now entered the normal range for the majority of surviving 
patients. Our previous data did not suggest an association between depth of 
lymphopenia and mortality or morbidity, so this is unlikely to represent ‘survival of the 
immunologically fittest’. There remain a significant number of patients with subnormal 
numbers of circulating CD8+ T-cells, B-cells and NK cells (Table 1).  
Our mortality statistics emphasise the poor outlook for RA patients with refractory 
disease at the end of the last century (11). Overall 48% of patients (combined cases 
and controls) had died at a median of 12.65 years since initial treatment, when the 
median age was approximately 54 years. There was no significant difference in 
mortality between cases and controls, who were selected from the EULAR database 
of RA patients treated with immunosuppressive drugs, mainly azathioprine or 
cyclophosphamide (Figure 1). The mortality rates in both cases and controls are at 
the higher end of published statistics for RA cohorts, consistent with the fact that 
these patients fall at the severe end of the disease spectrum. As per our previous 
publication, there was no difference in mortality according to the total dose of 
CAMPATH-1H received or the number of courses, some patients receiving up to 3 
courses of treatment (data not shown). The leading causes of death were those 
commonly seen in a cohort of RA patients: diseases of the circulatory, respiratory 
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and digestive systems. Diseases of the musculoskeletal system (RA in 5, septic 
arthritis in 2) featured prominently as a cause of death amongst controls but not 
cases. Deaths from neoplasms were more common in cases than in controls, 
although this did not reach statistical significance. One CAMPATH-1H recipient 
developed non-Hodgkin’s lymphoma, a known complication of severe RA, but the 
other tumours witnessed are not specifically associated with immunosuppressive 
conditions. Although these data might suggest a mild and selective 
immunodeficiency, mortality rates secondary to diseases of the digestive system had 
a similar incidence to neoplasms in cases and controls. These are more difficult to 
reconcile with an immunodeficiency state, suggesting that both statistics could 
represent chance findings in a small cohort of patients. It should also be noted that 
most CAMPATH-1H recipients subsequently received additional DMARDs. 
As with mortality, parameters of morbidity did not distinguish CAMPATH-1H  
recipients from other RA cohorts with refractory disease. Apart from a single case of 
disseminated Herpes zoster, no opportunistic infections were reported and the 
commonest sites for infection requiring intervention were the lungs, the skin 
(particularly lower extremities) and the joints. A large number of orthopaedic 
procedures were performed, the vast majority without infectious complications. 
Morbidity data are not available for our control cohort but in a recent study from the 
British Society for Rheumatology Biologics Registry, anti-TNF therapies were also 
associated with an increased incidence of serious infections affecting the skin and 
soft tissues (12). Three of our cases were using TNFα blockade at the time of follow-
up and several others had received these treatments in the interval since CAMPATH-
1H treatment (data not shown)  
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Our approaches to immunomodulation of autoimmune disease are becoming 
increasingly sophisticated. TNFα blockade, costimulation blockade and B-cell 
depletion are widely practised in RA and, increasingly, in other autoimmune 
conditions. As well as providing valuable new treatment opportunities, these 
therapies offer novel insights into immune physiology. One of these is that the human 
immune system has a high level of in-built redundancy - despite the potency of these 
therapies, infectious complications have been uncommon. Although our own 
experience is necessarily limited, it is one of the most remarkable: CAMPATH-1H 
rendered our patients pan-lymphopenic and it has taken up to12 years for them to 
regain normal lymphocyte counts; yet they have not appeared overtly 
immunosuppressed beyond the first few weeks after therapy. We have previously 
rehearsed the possible explanations for their immune sufficiency (3).  
In conclusion, we report long-term follow-up of patients that received one of the first 
biological therapies for RA. Despite profound biological effects of therapy, our 
patients have continued to behave like a cohort of patients with refractory RA. They 
have not displayed increased mortality or unusual morbidities. Notwithstanding the 
limited size of the original cohort, our data are reassuring in an era when potent 
biological therapies are being increasingly introduced for the management of RA (2). 
 
REFERENCES  
1. Hale G, Xia MQ, Tighe HP, Dyer MJ, Waldmann H. The CAMPATH-1 antigen 
(CDw52). Tissue Antigens 1990;35(3):118-27. 
2. Strand V, Kimberly R, Isaacs JD. Biologic therapies in rheumatology: lessons 
learned, future directions. Nat Rev Drug Discov 2007;6(1):75-92. 
Isaacs JD Page 12 14/05/2008 
3. Isaacs J, Greer S, Sharma S, Symmons D, Smith M, Johnston J, et al. 
Morbidity and mortality in rheumatoid arthritis patients with profound and prolonged 
therapy-induced lymphopenia. Arthritis Rheum 2001;44:1998-2008. 
4. Roll P, Palanichamy A, Kneitz C, Dorner T, Tony HP. Regeneration of B cell 
subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid 
arthritis. Arthritis Rheum 2006;54(8):2377-86. 
5. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC. Reconstitution of 
peripheral blood B cells after depletion with rituximab in patients with rheumatoid 
arthritis. Arthritis Rheum 2006;54(2):613-20. 
6. Kay A. EULAR register of patients on immunosuppressive drugs. Ann Rheum 
Dis 1982;41 Suppl 1:30-1. 
7. Isaacs JD, Thiel A. Stem cell transplantation for autoimmune disorders. 
Immune reconstitution. Best Pract Res Clin Haematol 2004;17(2):345-58. 
8. Ponchel F, Morgan A, Bingham S, Quinn M, Buch M, Verburg R, et al. 
Dysregulated lymphocyte proliferation and differentiation in patients with rheumatoid 
arthritis. Blood 2002;100:4550-6. 
9. Ponchel F, Verburg R, Bingham S, Brown A, Moore J, Protheroe A, et al. 
Interleukin-7 deficiency in rheumatoid arthritis: consequences for therapy-induced 
lymphopenia. Arthritis Res Ther 2005;7:R80-92. 
10. Cox AL, Thompson SA, Jones JL, Robertson VH, Hale G, Waldmann H, et al. 
Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple 
sclerosis. Eur J Immunol 2005;35(11):3332-42. 
11. Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, et al. The 
mortality of rheumatoid arthritis. Arthritis Rheum 1994;37(4):481-94. 
Isaacs JD Page 13 14/05/2008 
12. Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP. Rates of 
serious infection, including site-specific and bacterial intracellular infection, in 
rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from 
the British Society for Rheumatology Biologics Register. Arthritis Rheum 
2006;54(8):2368-76. 
 
 
 
Isaacs JD Page 14 14/05/2008 
TABLE 1. Duration of follow-up, current therapy and lymphocyte counts of patients 
included in current analysis (20 interviews, 5 case note analyses; patients 1, 24, 44 
and 50 died during the follow-up period). 
 
Patient 
reference 
number 
and sex 
Age at first 
treatment 
(y) 
Duration of 
follow-up 
(y) 
Current 
DMARDs 
Current* 
CD4+ 
count  
(x 109/L) 
Current 
CD8+ 
count 
(x 109/L) 
Current 
B-cell 
count 
(x 109/L) 
Current 
NK cell 
count 
(x 109/L) 
1F 69.00 13.25 Nil 0.68 0.59 0.16 0.12 
3F 54.08 12.00 Nil 0.26 0.31 0.02 0.23 
4F 60.50 11.92 MTX, INF 0.52 0.16 0.18 0.09 
5F 34.25 11.83 Aza 0.77 0.79 0.11 0.01 
6F 49.42 11.93 MTX N/A N/A N/A N/A 
10M 45.75 10.50 MTX, IM 
gold 
0.31 0.26 0.03 0.12 
14F 45.83 12.67 sc MTX 0.37 0.20 0.19 0.18 
15M 47.75 11.92 N/A N/A N/A N/A N/A 
16F 53.92 11.58 MTX 0.41 0.50 0.03 0.33 
17F 43.17 11.42 Nil 0.76 0.57 0.22 0.08 
18M 58.67 11.92 Nil 0.42 0.24 0.02 0.19 
21F 25.50 10.50 MTX 0.49 0.11 0.07 0.09 
24F 61.33 12.67 Aza 0.66 0.23 0.19 0.01 
26F 48.00 12.00 MTX, HQ 0.13 0.02 0.03 0.09 
27M 34.50 12.42 ETN 0.38 0.12 0.36 0.25 
29F 59.75 12.83 Nil 0.72 0.20 0.15 0.08 
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31F 43.75 12.02 MTX, Cic N/A N/A N/A N/A 
32F 53.58 11.50 Cic 0.96 0.63 0.23 0.21 
37F 64.50 11.58 Aza 0.79 0.33 0.06 0.02 
38F 64.42 11.83 ETN 0.68 0.51 0.11 0.27 
41F 52.75 10.83 Nil 0.46 0.14 0.05 0.09 
43F 71.67 12.67 N/A N/A N/A N/A N/A 
44F 53.08 11.00 Nil N/A N/A N/A N/A 
46F 47.50 11.75 MTX 1.68 0.58 0.40 0.08 
50M 41.08 11.83 Aza, HQ 0.29 0.26 0.09 0.02 
N/A, data not available; MTX, methotrexate; Aza, azathioprine; HQ, 
hydroxychloroquine; cic, ciclosporin; INF, infliximab; ETN, etanercept 
* Normal ranges for lymphocyte counts: 
CD3+CD4+, 0.3 - 1.4 x 109/L 
CD3+CD8+, 0.2 - 0.9 x 109/L 
CD19+, 0.1 - 0.5 x 109/L 
CD56+, 0.12 - 0.88 x 109/L 
 
 
 
 
 
 
 
 
TABLE 2. Mortality data for CAMPATH-1H recipients 
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A. Mortality from 01/01/1999 to 09/03/2006  
Patient 
reference 
number 
Age at 
1st  dose 
(years) 
Time from 
1st dose to 
death (years) 
Cause of death 
1 68.9 13.5 Ischemic heart disease, RA 
2 48.8 5.9 Primary sclerosing cholangitis, RA, 
Crohns Disease 
7 57.1 9.5 Metastatic leiomyosarcoma of stomach 
11 54.2 10.1 Bowel infarction secondary to atrial 
fibrillation 
20 64.3 6.2 Ischemic heart disease 
22 62.3 8.8 Upper gastro-intestinal bleed 
24 61.3 13.4 Ischemic heart disease 
30 55.4 8.8 Bronchopneumonia, multi infarct 
dementia 
39 66.5 4.8 Sigmoid bowel perforation (non-
malignant) 
40 50.1 11.6 Bronchopneumonia 
44 53.1 11.0 Ischemic heart disease 
45 71.2 7.4 Bronchopneumonia, pulmonary fibrosis 
49 68.3 12.6 Ischemic heart disease 
50 41.1 12.7 Small cell carcinoma of lung 
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B. Causes of death according to ICD code for entire cohort.   
ICD label controls 
(n=101) 
cases 
(n=51) 
Infectious & parasitic 1 1 
Neoplasms* 3 5 
Blood  1 0 
Endocrine, nutritional & metabolic 4 0 
Circulatory 16 10 
Respiratory 7 5 
Digestive 3 5 
Musculoskeletal 7 1 
Genito-urinary 1 0 
Injury & Poisoning 1 0 
External causes 1 0 
Unknown causes 1 0 
Total 46 27 
* One case each of non-Hodgkin’s lymphoma, lung squamous cell carcinoma, breast 
adenocarcinoma, colon adenocarcinoma and stomach leiomyosarcoma 
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FIGURE LEGENDS 
Figure 1. Kaplan-Meier survival plots for 51 rheumatoid arthritis patients who 
received CAMPATH-1H (cases) and 101 matched controls from the EULAR 
database. 
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FIGURE 1.  
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